glp-1-directed nmda receptor antagonism for obesity treatment New Developments in Pharmacological of and Type 2 Diabetes—Beyond and within GLP-1 Agonists A GIPR antagonist conjugated to

Suffer from Diabetes, Insulin Resistance, or PCOS

24 Management It is vital to effectively manage prediabetes in order to prevent and delay its progression to T2DM

We believe that significant efforts should be put into investigating in greater detail the pathways shared by eryptosis and erythronecroptosis, like caspase-8, ROS signaling, Fas/FasL signaling, to collect more evidence on the interplay between these erythrocyte-specific RCDs

In this systematic review, the authors conducted a comprehensive analysis of clinical trials to determine the impact of GLP-1 receptor agonists in reducing substance use disorder in patients